Leigh MacMillan Archive — Page 10 of 82

June 10, 2024

Vanderbilt researchers establish biomedical informatics training program in Mozambique

Building sustainable biomedical informatics training and research capacity to address gaps in Mozambique’s national HIV response will help the country leverage newer data-driven and genetics-based approaches for personalized HIV care and molecular epidemiology of the disease.

By Kristen Centers
June 6, 2024

Lakmini Kidder named Senior Vice President of Finance and Chief Revenue Officer

In her new capacity, Kidder will assume responsibility for overseeing all aspects of VUMC’s integrated revenue cycle, encompassing hospitals, clinics, the Vanderbilt Medical Group and Vanderbilt Integrated Providers.

June 5, 2024

A novel astrocyte cell in the retina: study

A full understanding of retinal cell types and their functions could point to novel therapeutic targets for diseases that affect the visual system, such as glaucoma — a leading cause of blindness for people over age 60.

By Leigh MacMillan
Photo caption: Jonathan Mosley, MD, PhD, left, Scott Borinstein, MD, PhD, John Shelley, and Vivian Kawai, MD, MPH, are studying how genetic variation not related to disease affects clinical decisions. (photo by Susan Urmy)
June 3, 2024

Genetic variation associated with low white blood cell count impacts clinical decisions

People whose white blood cell levels are near the edge of the “healthy” reference range will hit a clinical decision point that has consequences such as diagnostic procedures and altered treatments.

By Leigh MacMillan
(iStock)
May 21, 2024

NIH grant supports effort to build expertise in genetic epidemiology research in Vietnam

V2-GENE, the Vanderbilt-Vietnam Genetic Epidemiology Training Program, will develop a team of researchers and educators to lead genetic epidemiology research of noncommunicable diseases across the lifespan in Vietnam.

By Leigh MacMillan
May 8, 2024

Supercomputing redesign of a COVID monoclonal antibody

The approach, which combines high-performance computing, simulation, machine learning and experimental validation, will help keep antibody drugs up to date in the future against highly variable viruses.

By Leigh MacMillan